Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas

被引：0
|
作者：
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Moore, Malcolm J.
Teixeira, Luis
Siena, Salvatore
Tabernero, Josep
Goldstein, David
Wei, Xinyu
Lu, Brian
机构：
[1] Virginia G Piper Canc Ctr, Translat Genom Res Inst, Scottsdale, AZ USA
[2] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Hop St Antoine, F-75571 Paris, France
[5] Osped Niguarda Ca Granda, Falck Div Med Oncol, Milan, Italy
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Prince Wales Hosp, Sydney, NSW, Australia
[8] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页数：1
相关论文
共 42 条
  • [21] Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Mustapha Tehfe
    Scot Dowden
    Hagen Kennecke
    Robert El-Maraghi
    Bernard Lesperance
    Felix Couture
    Richard Letourneau
    Helen Liu
    Alfredo Romano
    Advances in Therapy, 2017, 34 : 277 - 279
  • [22] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
    Lacy, Jill
    Portales, Fabienne
    Hammel, Pascal
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Kim, Edward Jae-hoon
    Dowden, Scot D.
    Borg, Christophe
    Sastre, Javier
    Bathini, Venu Gopal
    Terrebonne, Eric
    Lopez-Trabada, Daniel
    Rivera, Fernando
    Asselah, Jamil
    Damiani, Azzurra
    Hwang, Jimmy J.
    Ong, Teng Jin
    Nydam, Thom
    Li, Jack Shiansong
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [23] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Goldstein, David
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [24] Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
    Tabernero, Josep
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl N.
    Romano, Alfredo
    Ferrara, Stefano
    Von Hoff, Daniel D.
    ONCOLOGIST, 2015, 20 (02): : 143 - 150
  • [25] APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] [18F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) plus gemcitabine (gem) for metastatic pancreatic cancer (MPC)
    Ramanathan, R.
    Von Hoff, D.
    Borad, M.
    Li, J. Shiansong
    McGovern, D.
    Renschler, M.
    Korn, R.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S118 - S118
  • [27] Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses
    Tempero, M. A.
    Reni, M.
    Riess, H.
    O'Reilly, E. M.
    Krishnamurthi, S.
    Osterlund, P.
    Ales-Diaz, I. C.
    Milella, M.
    Siena, S.
    Tabernero, J.
    Van Cutsem, E.
    Philip, P. A.
    Goldstein, D.
    Berlin, J. D.
    Li, M.
    Ferrara, S.
    Le Bruchec, Y.
    McGovern, D.
    Biankin, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
    Tempero, M. A.
    Cardin, D.
    Biankin, A.
    Goldstein, D.
    Moore, M.
    O'Reilly, E. M.
    Philip, P.
    Riess, H.
    Macarulla, T.
    Yung, L.
    Wei, X.
    Lu, B.
    PANCREAS, 2014, 43 (08) : 1416 - 1416
  • [29] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
  • [30] Impact of nab-paclitaxel (nab-P) plus gemcitabine (G) vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer patients with good or poor performance status at baseline: A post-hoc analysis of the MPACT trial
    Chiorean, E. G.
    Wan, Y.
    Whiting, S.
    Botteman, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S450 - S450
12345